Neoplasms, Neuroepithelial: Clinical Trials

4,150 trials for Neoplasms, Neuroepithelial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1878 completed, 654 recruiting, 465 terminated, 433 unknown. 1556 Phase 2, 1450 Phase 1, 526 Not applicable, 241 Phase 3, 174 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21556Completed 758, Terminated 208, Recruiting 202, Unknown 137, Active not recruiting 124, Withdrawn 61, Not yet recruiting 50, Suspended 9, Enrolling by invitation 7
Phase 11450Completed 723, Terminated 205, Recruiting 203, Active not recruiting 120, Unknown 86, Withdrawn 53, Not yet recruiting 43, Suspended 10, Enrolling by invitation 7
Not applicable526Completed 181, Recruiting 119, Unknown 80, Not yet recruiting 39, Terminated 34, Active not recruiting 33, Withdrawn 30, Suspended 7, Enrolling by invitation 3
Phase 3241Completed 111, Recruiting 39, Unknown 38, Active not recruiting 16, Terminated 16, Not yet recruiting 11, Withdrawn 9, Suspended 1
Early Phase 1174Completed 49, Recruiting 39, Terminated 26, Unknown 18, Active not recruiting 17, Not yet recruiting 13, Withdrawn 10, Enrolling by invitation 1, Suspended 1
Phase 418Completed 4, Recruiting 4, Active not recruiting 3, Not yet recruiting 2, Terminated 2, Unknown 2, Withdrawn 1

Follow Neoplasms, Neuroepithelial: new trials by email Literature Review of Neoplasms, Neuroepithelial trials Research Report on Neoplasms, Neuroepithelial

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma
Phase 1 / Phase 2RecruitingAssistance Publique Hopitaux De Marseille402032-02-012026-11-12
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
RNS System Implantation - Glioma, Glioma Intracranial
Not applicableNot yet recruitingMedical College of Wisconsin32028-08-012026-10-13
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma
Phase 1Not yet recruitingUniversität Münster302027-10-012026-11-03
Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)
Tarlatamab - High-Grade Glioma (HGG)
Phase 1Not yet recruitingVall d'Hebron Institute of Oncology102027-10-012026-11-12
Residual IDH1-Mutant Tumor Cell Quantification Study
UR-ddPCR - Glioma
Not applicableNot yet recruitingNYU Langone Health1052027-08-012026-09-29
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-10-30
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)762027-06-252026-11-18
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska412027-06-012026-10-05
DLL3 CAR-T Therapy Targeting Brain Tumors
4SCAR DLL3 T cells - Glioblastoma of Cerebellum
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-11-09
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
[F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma
Early Phase 1Not yet recruitingUniversity of Alabama at Birmingham282027-04-012026-08-20
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype
Phase 2 / Phase 3Not yet recruitingEverfront Biotech Co., Ltd.1752027-04-012026-09-10
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2Not yet recruitingNationwide Children's Hospital122027-03-012026-09-09
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Phase 3Not yet recruitingNuvation Bio Inc.1402027-03-012026-07-17
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
Safusidenib - Glioma : Oligodendroglioma or Astrocytoma
Phase 2Not yet recruitingUniversity of Zurich202027-03-012026-09-21
Oral Gallium Maltolate for Recurrent Glioblastoma
Gallium Maltolate, Surgical Intervention - Glioblastoma
Early Phase 1Not yet recruitingMedical College of Wisconsin82027-03-012026-09-23
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
Larotrectinib, Cadonilimab, Plixorafenib - IDH Wildtype Glioblastoma, Glioblastoma (GBM)
Early Phase 1Not yet recruitingOlivia Newton-John Cancer Research Institute122027-03-012026-10-30
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma
Phase 2RecruitingNuvation Bio Inc.402027-03-012026-11-10
A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.
Vorasidenib, Placebo, Temozolomide (TMZ) - IDH-mutant High-grade Astrocytoma
Phase 3Not yet recruitingInstitut de Recherches Internationales Servier5502027-03-012026-11-17

Showing 20 of 4150. Sign in to see all of them.

Narrower conditions

Glioblastoma (2076)  ·  Glioma (1454)  ·  Brain Neoplasms (897)  ·  Astrocytoma (681)  ·  Neuroblastoma (654)  ·  Gliosarcoma (487)  ·  Central Nervous System Neoplasms (445)  ·  Oligodendroglioma (411)  ·  Medulloblastoma (314)  ·  Neoplasms (283)  ·  Sarcoma (223)  ·  Ependymoma (220)  ·  Recurrence (202)  ·  Osteosarcoma (154)  ·  Breast Neoplasms (149)

Broader conditions

Neoplasms, Glandular and Epithelial (4146)  ·  Neoplasms, Nerve Tissue (4138)  ·  Neoplasms by Histologic Type (4137)  ·  Neuroectodermal Tumors (4131)  ·  Neoplasms, Germ Cell and Embryonal (4106)  ·  Neoplasms (3867)  ·  Glioma (1886)  ·  Neoplasms by Site (1730)  ·  Astrocytoma (1623)  ·  Nervous System Diseases (1428)  ·  Nervous System Neoplasms (1312)  ·  Central Nervous System Diseases (1102)  ·  Brain Diseases (1087)  ·  Neuroectodermal Tumors, Primitive (949)

Interventions

Temozolomide (575)  ·  Radiotherapy (329)  ·  Bevacizumab (210)  ·  Cyclophosphamide (174)  ·  Magnetic Resonance Spectroscopy (152)  ·  Carboplatin (150)  ·  Etoposide (136)  ·  Vincristine (123)  ·  Radiation (115)  ·  Irinotecan (106)  ·  Filgrastim (99)  ·  Cisplatin (81)  ·  Lomustine (78)  ·  Topotecan (77)  ·  Melphalan (71)

Sponsors

National Cancer Institute (NCI) (285)  ·  Children's Oncology Group (105)  ·  Memorial Sloan Kettering Cancer Center (100)  ·  M.D. Anderson Cancer Center (82)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (72)  ·  Duke University (70)  ·  St. Jude Children's Research Hospital (55)  ·  Mayo Clinic (39)  ·  Novartis Pharmaceuticals (38)  ·  Dana-Farber Cancer Institute (35)  ·  City of Hope Medical Center (33)  ·  Jonsson Comprehensive Cancer Center (33)  ·  European Organisation for Research and Treatment of Cancer - EORTC (32)  ·  Washington University School of Medicine (31)  ·  Case Comprehensive Cancer Center (30)

Countries

United States (2527)  ·  China (340)  ·  Canada (334)  ·  France (331)  ·  Germany (224)  ·  United Kingdom (207)  ·  Italy (187)  ·  Netherlands (181)  ·  Australia (180)  ·  Spain (175)  ·  Switzerland (158)  ·  Belgium (104)  ·  Austria (82)  ·  Denmark (73)  ·  South Korea (65)

Top investigators

Annick Desjardins, MD, FRCPC (16)  ·  Nader Sanai, MD (16)  ·  Stanislaw R. Burzynski, MD, PhD (16)  ·  David A. Reardon, MD (15)  ·  Giselle Sholler, MD (14)  ·  Henry S. Friedman, MD (14)  ·  David Peereboom, MD (12)  ·  John Boockvar, MD (12)  ·  Stuart A. Grossman, MD (12)  ·  Brian Kushner, MD (11)  ·  Maryam Fouladi, MD (11)

Results publications

PMID 31401903, PMID 23633099, PMID 34171339, PMID 38335473, PMID 19269895, PMID 32691060, PMID 36346112, PMID 38968568, PMID 39777725, PMID 15758009, PMID 23545055, PMID 24552317, PMID 25098701, PMID 25113840, PMID 29023494, PMID 29982805, PMID 34081125, PMID 34331515, PMID 35468680, PMID 37142373, PMID 37540556, PMID 12749708, PMID 16200343, PMID 16520474, PMID 17369569, PMID 17705175, PMID 19171714, PMID 19556464, PMID 19805691, PMID 20567002, PMID 20694800, PMID 20847174, PMID 20879881, PMID 21865400, PMID 22682017, PMID 23243055, PMID 23377664, PMID 23817721, PMID 23940216, PMID 24101040, PMID 24309981, PMID 24327518, PMID 24344045, PMID 24552318, PMID 24893855, PMID 25209242, PMID 26169613, PMID 27424289, PMID 27465021, PMID 27580889

NIH funding

U10CA098543 (49), U10CA180886 (45), P30CA033572 (24), U01CA062475 (23), U01CA081457 (23), 2023 (21), UM1CA081457 (18), 2009 (16), P01CA081403 (16), 2018 (15), 2014 (13), P30CA008748 (13), UM1CA137443 (13), 2017 (12), U10CA025224 (12)